About: Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Background In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. Aims The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. Methods We have an increasing group of (recently 42) MM patients. Overall clinical characteristics of the patients at the start of treatment: Average age 63.7 years (SD = 9.4), 57 % (24) of men. 12 % (5/42 pts) were in stage IA, 26 % (11/42 pts) were in stage IIA, 60 % (25/42 pts) were in stage IIIA and 2 % (1 patient) was in stage IIIB.
  • Background In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. Aims The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. Methods We have an increasing group of (recently 42) MM patients. Overall clinical characteristics of the patients at the start of treatment: Average age 63.7 years (SD = 9.4), 57 % (24) of men. 12 % (5/42 pts) were in stage IA, 26 % (11/42 pts) were in stage IIA, 60 % (25/42 pts) were in stage IIIA and 2 % (1 patient) was in stage IIIB. (en)
Title
  • Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
  • Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? (en)
skos:prefLabel
  • Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
  • Do the %22new drugs%22 antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? (en)
skos:notation
  • RIV/00216224:14110/07:00022791!RIV10-MSM-14110___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(LC06027)
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 417803
http://linked.open...ai/riv/idVysledku
  • RIV/00216224:14110/07:00022791
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • multiple myeloma; cIg FISH; velcade; thalidomide (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...ontrolniKodProRIV
  • [7B278766150D]
http://linked.open...v/mistoKonaniAkce
  • Budapest, Hungary
http://linked.open...i/riv/mistoVydani
  • Edinburgh
http://linked.open...i/riv/nazevZdroje
  • Blood reviews
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...iv/tvurceVysledku
  • Adam, Zdeněk
  • Hájek, Roman
  • Krejčí, Marta
  • Kuglík, Petr
  • Pour, Luděk
  • Němec, Pavel
  • Filková, Hana
  • Oltová, Alexandra
  • Grešliková, Henrieta
  • Křivanová, Andrea
  • Zaoralová, Romana
  • Smejkalová, Jana
http://linked.open...vavai/riv/typAkce
http://linked.open.../riv/zahajeniAkce
issn
  • 0268-960X
number of pages
http://purl.org/ne...btex#hasPublisher
  • Churchill Livingstone
http://localhost/t...ganizacniJednotka
  • 14110
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software